BROOKE MCGUIRE: Open Payments
NPI 1780952127 · STANLEY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$616 in 38 payments from 9 companies in 2025. Trend: 2023 $725 · 2024 $670 · 2025 $616
Food & beverage: $616
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $271 |
| Lilly USA, LLC | 5 | $90 |
| ABBVIE INC. | 2 | $56 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Abbott Laboratories | 2 | $39 |
| Amgen Inc. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: Ozempic, MOUNJARO, XIFAXAN, AIRSUPRA, Wegovy, FREESTYLE LIBRE 3, EVENITY, QULIPTA.
Industry payments across KS — which companies pay providers there.
